Critical Contrast: Affymax (AFFY) and Soligenix (SNGX)
Affymax (OTCMKTS: AFFY) and Soligenix (OTC:SNGX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, analyst recommendations and earnings.
Valuation & Earnings
This table compares Affymax and Soligenix’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Soligenix||$6.98 million||1.84||-$6.76 million||N/A||N/A|
Soligenix has higher revenue and earnings than Affymax.
This is a breakdown of recent ratings and recommmendations for Affymax and Soligenix, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Soligenix has a consensus price target of $8.00, suggesting a potential upside of 255.56%. Given Soligenix’s higher possible upside, analysts plainly believe Soligenix is more favorable than Affymax.
This table compares Affymax and Soligenix’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Affymax Company Profile
Affymax, Inc. is a biopharmaceutical company. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The Company has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.
Soligenix Company Profile
Soligenix, Inc. is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. Its Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate.
Receive News & Ratings for Affymax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.